Plasma levels of the three endothelial-specific proteins von Willebrand factor, tissue factor pathway inhibitor, and thrombomodulin do not predict the development of acute respiratory distress syndrome

Bajaj, Monika; Tricomi, Sally M.

doi:10.1007/s001340050097

Cited by 10 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Authors conducted the first study comparing plasma levels between survivors and nonsurvivors in a group of patients both at risk for and with established ARDS and observed no significant association of VWF blood levels with patients' mortality ;predictive value of the marker was not reported. In agreement with the previous study, a study from the same group of scientists {Bajaj et al [53]} using standard criteria for the definition of ARDS and at risk state [3] demonstrated the inability of three endothelial-specific proteins including VWF to predict the progression of ARDS in at risk patients. Nonetheless, major caveats that should be addressed include the fact that many at-risk patients had already some degree of ALI, the lack of serial measurement that could potentially show a trend towards prediction of ARDS development and the causal diversity of patients examined that could possibly affect the results of the study.…”

Section: Other Serological Parameterssupporting

confidence: 88%

“…Finally, only the minority of the studies [18,19,25-27,43,45,47,51,53,64,66,67,83,86,95] clarified the effectiveness and the diagnostic accuracy of the biomarkers by applying ROC curve analysis which is essential to estimate the sensitivity and specificity of a marker and to introduce clinically practical cut-off levels for the prediction of ARDS development in at risk individuals.…”

Section: Future Challenges and Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Serum biomarkers in Acute Respiratory Distress Syndrome an ailing prognosticator

2005

View full text Add to dashboard Cite

Serum biomarkersacute respiratory distress syndromeacute lung injurycytokinesKL-6surfactant proteinsadhesion molecules. AbstractThe use of biomarkers in medicine lies in their ability to detect disease and support diagnostic and therapeutic decisions. New research and novel understanding of the molecular basis of the disease reveals an abundance of exciting new biomarkers who present a promise for use in the everyday clinical practice. The past fifteen years have seen the emergence of numerous clinical applications of several new molecules as biologic markers in the research field relevant to acute respiratory distress syndrome (translational research). The scope of this review is to summarize the current state of knowledge about serum biomarkers in acute lung injury and acute respiratory distress syndrome and their potential value as prognostic tools and present some of the future perspectives and challenges.

show abstract

Section: Other Serological Parameterssupporting

confidence: 88%

Section: Future Challenges and Limitationsmentioning

confidence: 99%

Serum biomarkers in Acute Respiratory Distress Syndrome an ailing prognosticator

2005

View full text Add to dashboard Cite

show abstract

“…In ALI, the plasma and BALF levels of protein C (part of the APC complex) are low and the plasma levels of PAI-1 are elevated, and both of these findings have been associated with increased mortality 26, 99, 106, 107. Therefore there was a rationale for drug trials in patients with ALI with therapeutic interventions focused on administering pharmacologic doses of human recombinant APC 108, 109, 110, 111. Based on in vitro studies, APC can protect the endothelial barrier via protease activated receptor-1 (PAR-1) dependent mechanisms.…”

Section: Inflammationmentioning

confidence: 99%

Biomarkers in Acute Lung Injury: Insights into the Pathogenesis of Acute Lung Injury

Cross

Matthay

2011

Critical Care Clinics

208

182

View full text Add to dashboard Cite

Studies of potential biomarkers in experimental models of acute lung injury (ALI) and from clinical samples from patients with ALI have provided extensive information relating to the pathophysiology of the mechanisms of lung injury and repair. The utility of biomarkers remains still solely part of the research tools to investigate lung injury and repair mechanisms and due to lack of sensitivity and specificity cannot yet be used as a clinical decision tool in patients with either acute lung injury or ARDS. We have reviewed known biomarkers in context of their major biological activity such as inflammatory mediators, coagulation/fibrinolytic mediators, growth factors and the emerging use of proteomics. The continued interest in identifying and studying biomarkers is relevant as it continues to provide important information regarding the mechanisms involved in lung injury and repair and how this may be helpful in the identification and design of future therapeutic targets and strategies as well as hopefully to identify a sensitive and specific biomarker that would be of clinical relevance.

show abstract

“…The assay has been found to be reliable in measuring TFPI levels in conditioned media of a variety of cells [10,16,19], in plasma [26,27] and in body fluids [26]. Since no other known factor inhibits the VIIa/TF-catalysed activation of sialyl 3 H-IX in the presence of factor Xa, this assay becomes highly specific for TFPI [26,27]. Moreover, the functional assay for TFPI activity has been shown to highly correlate with TFPI antigen [28].…”

Section: Cell Culturesmentioning

confidence: 99%

Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells

et al. 2000

View full text Add to dashboard Cite

Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells. M.S. Bajaj, U. Pendurthi, K. Koenig, S. Pueblitz, S. Idell. #ERS Journals Ltd 2000. ABSTRACT: The mesothelial lining of the pleura and malignant mesothelioma promote fibrin deposition in pleural injury or neoplasia via expression of tissue factor (TF). It was hypothesized that these cells might also regulate intrapleural coagulation by elaborating TF pathway inhibitor (TFPI).TFPI activity and antigen in pleural fluids were assayed from patients with congestive heart failure (CHF), pneumonia, empyema, metastatic pleural cancer and malignant mesothelioma. The authors also assessed expression of TF and TFPI messenger ribonucleic acid (mRNA) as well as TFPI activity and antigen by human pleural mesothelial cells, malignant mesothelioma cells (MS-1 cell line) and human lung fibroblasts. Immunohistochemical analyses of normal, fibrotic, and neoplastic pleura were performed to determine whether TFPI antigen was expressed in vivo.The study revealed that TFPI was present in transudates from patients with CHF and exudative pleural effusions from patients with pneumonia, empyema or pleural carcinoma. TFPI mRNA, activity and antigen were expressed by pleural mesothelial cells, MS-1 cells and lung fibroblasts. Cytokines and serum stimulated a significant early increase in TF mRNA levels with minimal enhancement of TFPI mRNA, activity and antigen levels. TFPI antigen was found in normal, fibrotic and neoplastic pleural tissues.The current observations indicate that tissue factor pathway inhibitor is locally expressed in pleural disease, but that it does not prevent the development of a prothrombotic environment favouring local fibrin deposition in pleural inflammation or cancer. Eur Respir J 2000; 15: 1069±1078.

show abstract

Plasma levels of the three endothelial-specific proteins von Willebrand factor, tissue factor pathway inhibitor, and thrombomodulin do not predict the development of acute respiratory distress syndrome

Cited by 10 publications

References 0 publications

Serum biomarkers in Acute Respiratory Distress Syndrome an ailing prognosticator

Serum biomarkers in Acute Respiratory Distress Syndrome an ailing prognosticator

Biomarkers in Acute Lung Injury: Insights into the Pathogenesis of Acute Lung Injury

Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells

Contact Info

Product

Resources

About